New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA
- Written by PR Newswire
SHANGHAI, Dec. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the new drug application of its recombinant (yeast-secreted) human serum albumin-human granulocyte colony-stimulating factor (I) fusion protein for injection (R&D code: 8MW0511) has been accepted...
Read more: New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA














